Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
Posted on: Tuesday, 18 August 2009, 10:25 CDT
WELLESLEY HILLS, Mass., Aug. 18 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction.
The PRX-08066 is a Therapeutics Program in Phase 2 for respiratory indication. It is a small molecule, oral 5HT2b antagonist for potential treatment of pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD). There is significant reduction in SPAP in conditioned athletes (hypoxia challenge) and in subjects with PH/COPD. There is potential indication for pulmonary arterial hypertension (PAH) including in diastolic dysfunction.
The intellectual property, regulatory dossier and clinical inventory will be sold at auction on September 30, 2009.
Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net
SOURCE Joseph F. Finn, Jr., C.P.A.
Source: PR Newswire
Related Articles
- Savara Expands Board of Directors, Appoints Three New Members
- Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM)
- Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
- Aradigm and Lung Rx Agree to Develop AERx Essence(R) Technology for Use in Pulmonary Arterial Hypertension
- Y's Therapeutics Initiates Phase II Trial With YSPSL in Liver Transplant Patients for Prevention of Ischemic Reperfusion (I/R) Injury
- Progress Analysis of Top 7 Cancer Indications, Including Players, Drugs, Clinical Progress and Pitfalls
- Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension*
- Semiquantitative ^Sup 67^Ga Scintigraphy As an Indicator of Response to and Prognosis After Corticosteroid Treatment in Idiopathic Interstitial Pneumonia
- Viagra Study Spotlights Pulmonary Hypertension
 |
 |
User Comments (0)
RSS Feeds